One stock to keep an eye on is Novartis (NVS). NVS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 13.33. This compares to its ...

ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...

The move is being watched closely by the Australian government, which is wary of how criminal groups and the Chinese government could exploit the bank's presence in PNG. The Bank of China is ...

PNG's foreign minister Justin Tkatchenko announced last week that PNG would not participate in the 29th United Nations Convention on Climate Change Conference of Parties (UNFCC COP29) in protest and ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Novartis (Symbol: NVS) entered into oversold territory, hitting an RSI reading of 29.9 ...

When I (Kody) last covered Novartis with a buy rating in May, I liked its continuity as a business. The company's product portfolio and pipeline were also impressive. Novartis' balance sheet was ...

TD Cowen analyst Steve Scala maintained a Hold rating on Novartis (NVS – Research Report) today. The company’s shares closed yesterday at $110.53. Scala covers the Healthcare sector ...

The expanded indication increases the eligible patient population by approximately four times, according to Novartis. The FDA on Tuesday approved the expansion of Novartis’ Scemblix for the treatment ...

Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

One of the largest pharmaceutical companies in the world, Novartis AG, has posted strong quarterly results. It comes on the back of major growth in demand for its flagship medicines. This has led ...

Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live webcast. [Operator instructions] With that, I would like to hand over to Ms. Sloan ...